NOVEL LIVE MULTI-ANTIGENIC RECOMBINANT VACCINE AGAINST TUBERCULOSIS
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a deadly global disease. Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Europäisches Patentamt - (2023) vom: 26. Okt. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
HORWITZ MARCUS A [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-10-26, Last update posted on www.tib.eu: 2023-12-22, Last updated: 2023-12-29 |
---|
Patentnummer: |
WO2023159121 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA017921295 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA017921295 | ||
003 | DE-627 | ||
005 | 20231229111129.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230915s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA017921295 | ||
035 | |a (EPA)WO2023159121 | ||
035 | |a (EPA)87579134 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a HORWITZ MARCUS A |e verfasserin |4 aut | |
245 | 1 | 0 | |a NOVEL LIVE MULTI-ANTIGENIC RECOMBINANT VACCINE AGAINST TUBERCULOSIS |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2023-10-26, Last update posted on www.tib.eu: 2023-12-22, Last updated: 2023-12-29 | ||
520 | |a Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a deadly global disease. Embodiments of the invention comprise an improved vaccine for generating an immune response and preventing or treating mycobacterial diseases such as tuberculosis in humans and animals. Embodiments of the invention also comprise a method for using the vaccine against such mycobacterial diseases. | ||
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a JIA QINGMEI |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 26. Okt. |
773 | 1 | 8 | |g year:2023 |g day:26 |g month:10 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87579134/publication/WO2023159121A1?q=WO2023159121 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
936 | u | w | |j 2023 |b 26 |c 10 |
951 | |a AR | ||
952 | |j 2023 |b 26 |c 10 |